CNMD
CONMED Corporation
CNMD's fundamentals are mixed, but it looks cheap: trading at 21x earnings, below its usual 36x. Analysts expect earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CNMD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Weak |
CNMD's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is weak.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CNMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 11x | $50.48 | — |
| Cheap | 17x | $41.30 | -18% |
| Current | 21x | $50.48 | — |
| Fair | 36x | $86.56 | +71% |
| Expensive | 76x | $185 | +266% |
Historical ranges are pointers, not guarantees.
CNMD's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 11x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CNMD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect CNMD's earnings to grow, with its revenue and profitability holding steady.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CNMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.63 | +91% |
| Q3 2026 | $2.42 | +17% |
| Q2 2026 | $1.85 | -48% |
| Q1 2026 | $1.77 | -54% |
| Q4 2025 | $1.51 | -64% |
| Q3 2025 | $2.06 | -51% |
| Q2 2025 | $3.54 | +13% |
| Q1 2025 | $3.81 | +46% |
| Q4 2024 | $4.25 | +108% |
CNMD has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CNMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $335.6M | -0.7% |
| Q2 2026 | $343.5M | +0.3% |
| Q1 2026 | $317M | -1.3% |
| Q4 2025 | $373.2M | +7.9% |
| Q3 2025 | $337.9M | +6.7% |
| Q2 2025 | $342.3M | +3.1% |
| Q1 2025 | $321.3M | +2.9% |
| Q4 2024 | $345.9M | +5.8% |
CNMD's revenue grew through 2024 and has held roughly level since: $336M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | +7.6 points |
| Q2 2026 | 11% | -0.6 points |
| Q1 2026 | 8% | +3 points |
| Q4 2025 | 9.8% | -5.4 points |
| Q3 2025 | 3.5% | -17 points |
| Q2 2025 | 11% | -3 points |
| Q1 2025 | 5% | -6.2 points |
| Q4 2024 | 15% | -0.2 points |
CNMD has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CNMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
CNMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $46.7M | -3.7% |
| Q2 2026 | $34.2M | +46% |
| Q1 2026 | $10.6M | -72% |
| Q4 2025 | $41.2M | +4.9% |
| Q3 2025 | $48.5M | +1.5% |
| Q2 2025 | $23.4M | -41% |
| Q1 2025 | $37.8M | +39% |
| Q4 2024 | $39.3M | -24% |
CNMD generated $133M in free cash flow over the past year, down 11% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CNMD on cash flow, with more consistent year-over-year improvement.
CNMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +8K shares |
| 1 year | -3% | -925K shares |
| 3 years | -4.9% | -1.6M shares |
| 5 years | -6.3% | -2M shares |
| Available history | +2.1% | +630K shares |
CNMD has 30M diluted shares, down 3% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6.2M |
| Q2 2026 | $6.2M |
| Q1 2026 | $37M |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CNMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CNMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.3x | High |
| Q2 2026 | 5.2x | High |
| Q1 2026 | 5.3x | High |
| Q4 2025 | 5.1x | High |
| Q3 2025 | 4.8x | High |
| Q2 2025 | 3.8x | Elevated |
| Q1 2025 | 3.7x | Elevated |
| Q4 2024 | 3.5x | Elevated |
CNMD's net debt is about 4.3 years of its operating earnings (EBITDA), down from 4.8 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CNMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.0 | Neutral |
| Stochastic | 49.0 | Neutral |
CNMD's weekly RSI is 59 (neutral) and its Stochastic is 49 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CNMD PE vs Healthcare Sector
| Metric | CNMD | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 19% below |
| PE % | 26 | 29 | 3 pts below |
CNMD is trading at 21x earnings, a 19% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CNMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.3 | 6.7% above |
| 20 week MA | $46.2 | 9.2% above |
| 50 week MA | $41.7 | 21% above |
| 100 week MA | $48.5 | 4.2% above |
| 200 week MA | $70.6 | 29% below |
CNMD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CNMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $110.5 | $112.8 | +2.1% |
| 2021 | $112.8 | $142.0 | +26% |
| 2022 | $142.0 | $86.8 | -39% |
| 2023 | $86.8 | $109.5 | +26% |
| 2024 | $109.5 | $70.6 | -36% |
| 2025 | $70.6 | $40.8 | -42% |
| 2026 YTD | $40.8 | $50.5 | +24% |
CNMD has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.